Operating cash flow has deteriorated to an $81.7 million deficit in 2025Q3, highlighting the accelerating capital requirements needed to support ongoing clinical development.
| Cash from Operations | -231.4M | -99.79M | -35.39M |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | -188.76% | -181.94% | - |
| Net Income | -314.41M | -209.13M | -47.21M |
| Depreciation & Amortization | 35K | 14K | 2K |
| Stock-Based Compensation | 7.84M | 0 | 85K |
| Deferred Taxes | 0 | -9.34M | 0 |
| Other Non-Cash Items | 59.98M | 92.92M | 7.7M |
| Working Capital Changes | 15.16M | 25.75M | 4.02M |
| Change in Receivables | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 8.73M | 16.55M | 2.6M |
| Cash from Investing | -199K | -43K | -28.24M |
| Capital Expenditures | -199K | -43K | -29K |
| CapEx % of Revenue | - | - | - |
| Acquisitions | 0 | 0 | -28.21M |
| Investments | - | - | - |
| Other Investing | 0 | 0 | 0 |
| Cash from Financing | 489.63M | 377.95M | 123.68M |
| Debt Issued (Net) | -125K | -252K | 0 |
| Equity Issued (Net) | 2.33M | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 |
| Other Financing | -14.11M | -18.98M | -217K |
| Net Change in Cash | 260.87M | 277.25M | 60.22M |
| Free Cash Flow | -231.59M | -99.83M | -35.42M |
| FCF Margin % | - | - | - |
| FCF Growth % | - | -181.83% | - |
| FCF per Share | -2.21 | -0.97 | -0.71 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.48x | 0.75x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
Accelerating clinical cash burn
According to recent financial disclosures, Metsera's operating cash flow reached a deficit of $81.7 million in 2025Q3, representing a significant deterioration from the $28.3 million outflow observed in 2024Q3, as the company intensifies its clinical development efforts across its proprietary metabolic therapeutic pipeline.
The divergence between net income and operating cash flow suggests that non-cash expenses remain minimal, confirming that the reported losses are primarily driven by actual cash-intensive R&D activities. Investors should monitor the OCF/NI ratio, which currently sits at 0.70, indicating that cash burn is tracking closely with accounting losses as the company lacks any revenue-based offsets.
As reported in quarterly filings, Metsera's free cash flow has trended toward deeper negative territory, moving from a $28.3 million outflow in 2024Q3 to an $81.7 million outflow by 2025Q3, reflecting the escalating capital requirements necessary to support late-stage clinical trial recruitment and infrastructure.
The consistent negative FCF trajectory is characteristic of a pre-revenue biotech firm, yet the acceleration in burn rate warrants caution regarding the company's long-term liquidity runway. Without a clear path to commercialization, this trend suggests that the firm remains entirely dependent on external capital markets to sustain its current research velocity.
Based on the latest quarterly data, Metsera experienced a $15.6 million negative swing in working capital during 2025Q3, a sharp reversal from the positive contributions seen in previous quarters, which may indicate timing mismatches in vendor payments or clinical trial site management expenses.
This volatility in working capital suggests that the company's cash position is sensitive to the timing of clinical trial milestones and associated service provider invoices. Analysts should investigate whether this shift represents a structural change in payment terms or merely a temporary fluctuation in the timing of R&D-related liabilities.
Data from recent SEC filings indicate that Metsera's cash burn is accelerating, with the company recording an $81.7 million operating loss in 2025Q3, which may force management to seek additional capital markets access sooner than the current market consensus might anticipate given the current cash position.
While the company maintains a cash balance of $352.4 million, the rapid escalation in quarterly burn suggests that the runway may be shorter than the headline figures imply. Investors should be wary of the potential for future dilutive financing events if the current pace of clinical investment continues to outstrip the company's existing liquidity reserves.
Quick answers to the most common questions about buying MTSR stock.
Metsera, Inc. (MTSR) generated $-99.8M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Metsera, Inc. (MTSR) reported negative free cash flow of $99.8M in 2024, indicating capital requirements exceeded cash from operations.
Metsera, Inc. (MTSR) spent $0.0M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.